London-based Isomorphic Labs, an AI-first drug design company spun out of Google DeepMind (Alphabet), has secured $2.1 billion in Series B funding—announced on May 12, 2026. This major round significantly exceeds the earlier reports of “over $2 billion” and marks one of the largest AI healthcare funding deals this year.
The financing was led by Thrive Capital, which also led Isomorphic’s previous $600 million round in March 2025. Existing backers Alphabet and GV participated alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, expanding the company’s global capital base.
Isomorphic Labs uses advanced artificial intelligence to revolutionize drug discovery. Their AI drug design engine aims to shorten development timelines, reduce costs, and identify new treatments across multiple therapeutic areas like cancer and rare diseases. The fresh capital will scale their AI platform, accelerate clinical pipelines, and strengthen partnerships with pharmaceutical companies worldwide.
This funding highlights growing investor confidence in AI-driven healthcare innovation. With Google DeepMind’s breakthrough models behind the technology, Isomorphic is positioned to transform how new medicines are designed and brought to patients.
FAQs [Frequently Asked Questions]
1. What is Isomorphic Labs?
Isomorphic Labs is an AI-first drug design company spun from Google DeepMind, using artificial intelligence to discover and develop new pharmaceutical treatments faster.
2. How much funding did Isomorphic Labs raise?
The company raised $2.1 billion in Series B funding on May 12, 2026, led by Thrive Capital with participation from Alphabet, GV, Temasek, and others.
3. What will the funding be used for?
Funds will scale Isomorphic’s AI drug design engine, accelerate clinical pipelines across therapeutic areas, and strengthen partnerships with pharmaceutical companies globally.